Construction of miRNA-lncRNA-mRNA co-expression network affecting EMT-mediated cisplatin resistance in ovarian cancer

Amirhosein Naghsh-Nilchi1, Laleh Ebrahimi Ghahnavieh1, Fariba Dehghanian1

  • 1Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.

Insights

Platinum resistance in ovarian cancer is linked to epithelial-mesenchymal transition (EMT). The brown module

Area of Science:

  • Genomics and Bioinformatics
  • Oncology
  • Molecular Biology

Background:

  • Platinum resistance is a major challenge in ovarian cancer treatment.
  • Epithelial-mesenchymal transition (EMT) plays a critical role in platinum resistance.
  • Epithelial-like ovarian cancer cells exhibit reduced sensitivity to cisplatin post-treatment.

Purpose of the Study:

  • To investigate the association between epithelial phenotype and cisplatin response in ovarian cancer.
  • To identify potential biomarkers for predicting cisplatin resistance in ovarian cancer.

Main Methods:

  • Acquisition and analysis of microarray dataset GSE47856 from the GEO database.
  • Weighted gene co-expression network analysis (WGCNA) to identify gene modules associated with epithelial phenotype.
  • Gene Ontology (GO), KEGG pathway, protein-protein interaction network, and survival analyses were performed.

Main Results:

  • Twenty modules related to the epithelial phenotype were identified, with antiquewhite4, brown, and darkmagenta modules being most significant.
  • Enrichment analyses revealed enrichment in focal adhesion, DNA replication, and stress response pathways.
  • The co-expression pattern of hub genes within the brown module showed potential as a prognostic biomarker.

Conclusions:

  • The study highlights the link between epithelial phenotype and cisplatin resistance in ovarian cancer.
  • Hub genes within the brown module, identified through WGCNA, may serve as prognostic biomarkers for ovarian cancer cisplatin resistance.
  • Further validation is warranted to confirm the clinical utility of these biomarkers.